Welton N J, Cooper N J, Ades A E, Lu G, Sutton A J
Academic Unit of Primary Health Care, Department of Community Based Medicine, University of Bristol, Cotham House, Cotham Hill, Bristol BS6 6JL, U.K.
Stat Med. 2008 Nov 29;27(27):5620-39. doi: 10.1002/sim.3377.
We present a mixed treatment meta-analysis of antivirals for treatment of influenza, where some trials report summary measures on at least one of the two outcomes: time to alleviation of fever and time to alleviation of symptoms. The synthesis is further complicated by the variety of summary measures reported: mean time, median time and proportion symptom free at the end of follow-up. We compare several models using the deviance information criteria and the contribution of different evidence sources to the residual deviance to aid model selection. A Weibull model with exchangeable treatment effects that are independent for each outcome but have a common random effect mean for the two outcomes gives the best fit according to these criteria. This model allows us to summarize treatment effect on two outcomes in a single summary measure and draw conclusions as to the most effective treatment. Amantadine and Oseltamivir were the most effective treatments, with the probability of being most effective of 0.56 and 0.37, respectively. Amantadine reduces the duration of symptoms by an estimated 2.8 days, and Oseltamivir 2.6 days, compared with placebo. The models provide flexible methods for synthesis of evidence on multiple treatments in the absence of head-to-head trial data, when different summary measures are used and either different clinical outcomes are reported or where the same outcomes are reported at different or multiple time points.
我们对用于治疗流感的抗病毒药物进行了混合治疗荟萃分析,其中一些试验报告了关于两个结局中至少一个的汇总指标:发热缓解时间和症状缓解时间。所报告的汇总指标种类繁多,使得合成过程更加复杂:平均时间、中位数时间以及随访结束时无症状的比例。我们使用偏差信息准则以及不同证据来源对残差偏差的贡献来比较几种模型,以辅助模型选择。根据这些准则,对于每个结局具有独立可交换治疗效应但两个结局具有共同随机效应均值的威布尔模型拟合效果最佳。该模型使我们能够在单一汇总指标中总结对两个结局的治疗效果,并得出关于最有效治疗方法的结论。金刚烷胺和奥司他韦是最有效的治疗药物,其最有效的概率分别为0.56和0.37。与安慰剂相比,金刚烷胺估计可将症状持续时间缩短2.8天,奥司他韦可缩短2.6天。当没有直接对比试验数据、使用不同汇总指标、报告不同临床结局或在不同或多个时间点报告相同结局时,这些模型为综合多种治疗的证据提供了灵活的方法。